Lupin gets nod for Keppra generic

Reuters
Posted: Friday, Jan 16, 2009 at 1307 hrs IST
Updated: Friday, Jan 16, 2009 at 1307 hrs IST

Font Size

Feedback

Discuss

GSK Pharma Q3 profit rises 7%Dr Reddy's Q2 net up 3 fold at Rs 240 cr Piramal Healthcare Q2 net up 45 pct Ranbaxy hails US court ruling on Valcyte patent

Mumbai: Indian drug maker Lupin said on Friday it has received final US Food and Drug Administration approval to sell the generic levetiracetam tablet in multiple strengths.

The drug is prescribed for the treatment of partial seizures in adults and children with epilepsy, and had sales of about $1.2 billion for the 12 months to September 2008, the company said in a statement.

Earlier in the day, India's Glenmark Pharmaceuticals Ltd , Aurobindo Pharma and Orchid Chemicals also said they had secured FDA approval to launch the generic version of UCB's Keppra in the US.

Post Comments

Comments: (Limit 3,000 characters)

Name		Message
Email ID
Subject

TERMS OF USE:
The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).

I agree to the terms of use.